Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

K Daniel Spiegelman

Affiliations

  • Evp, Chief Financial Officer at Biomarin Pharmaceutical Inc (BMRN), 2019-06-07
  • Director at Cascadian Therapeutics Inc. (CASC), 2018-03-13
  • Director at Relypsa Inc (RLYP), 2016-09-02
  • at Anthera Pharmaceuticals Inc (ANTH), 2014-06-16
  • Director at Affymax Inc (AFFY), 2012-06-18
  • Director at Omeros Corp (OMER), 2012-06-04
  • Director at Cyclacel Pharmaceuticals Inc. (CYCC), 2012-05-25
  • Officer at Cv Therapeutics Inc (CVTX), 2009-04-09
Insider Trading: Purchases See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
ONTY $1.59 10,000 Director 40,644 2015-03-26 Filing
ONTY $1.63 10,000 Director 30,644 2015-03-25 Filing
ONTY $1.59 10,000 Director 40,644 2015-03-26 Filing
ONTY $1.63 10,000 Director 30,644 2015-03-25 Filing
Insider Trading: Sales See All
Company Symbol Price Amount Relationship Remaining Holdings Date Form 4
BMRN $89.00 13,473 Officer 47,510 2019-04-01 Filing
BMRN $90.00 100 Officer 60,983 2019-03-27 Filing
BMRN $99.01 472 Officer 51,070 2018-06-22 Filing
BMRN $99.00 9,528 Officer 51,542 2018-06-22 Filing
BMRN $82.15 11,059 Officer 62,543 2018-04-23 Filing